Dooley D P, Cox R A, Looney D J
Department of Research Immunology, San Antonio State Chest Hospital, TX 78223.
Clin Exp Immunol. 1991 Feb;83(2):192-6. doi: 10.1111/j.1365-2249.1991.tb05613.x.
An investigation was undertaken to determine whether a recombinant gp160 envelope protein, which is currently being evaluated as a vaccine for AIDS, induces or modulates the production of tumour necrosis factor-alpha (TNF-alpha) or interleukin-1 beta (IL-1 beta). Incubation of monocytes from healthy, HIV-seronegative persons with 0.0001-1.0 micrograms of the recombinant vaccine did not result in the secretion of TNF-alpha or IL-1 beta, nor did the recombinant product augment or suppress monokine production by lipopolysaccharide (LPS) stimulated monocytes. The vaccine was also without a stimulatory or modulatory effect upon TNF-alpha or IL-1 beta secretion by monocytes from a patient with the AIDS-related complex (ARC) and from the monocytic THP-1 cell line. The lack of effect of gp160 on monokine production has important implications for its efficacy as a vaccine for AIDS.
开展了一项调查，以确定一种重组gp160包膜蛋白（目前正作为艾滋病疫苗进行评估）是否诱导或调节肿瘤坏死因子-α（TNF-α）或白细胞介素-1β（IL-1β）的产生。将健康的HIV血清阴性者的单核细胞与0.0001 - 1.0微克重组疫苗一起孵育，并未导致TNF-α或IL-1β的分泌，该重组产品也未增强或抑制脂多糖（LPS）刺激的单核细胞产生单核因子。该疫苗对艾滋病相关综合征（ARC）患者的单核细胞以及单核细胞THP-1细胞系分泌TNF-α或IL-1β也没有刺激或调节作用。gp160对单核因子产生缺乏影响对其作为艾滋病疫苗的疗效具有重要意义。
